I-Mab Stock (NASDAQ:IMAB)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.95

52W Range

$0.90 - $2.54

50D Avg

$1.11

200D Avg

$1.43

Market Cap

$71.09M

Avg Vol (3M)

$420.46K

Beta

1.08

Div Yield

-

IMAB Company Profile


I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

CN

Employees

34

IPO Date

Jan 17, 2020

Website

IMAB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Supply Of Investigational Products$10.83M$28.10M$47.91M
Licensing and Collaboration$16.81M$-249.66M$40.12M

Fiscal year ends in Dec 23 | Currency in USD

IMAB Financial Summary


Dec 23Dec 22Dec 21
Revenue$27.64M$-221.56M$88.03M
Operating Income$-1.24B$-1.87B$-2.07B
Net Income$-1.47B$-2.41B$-2.33B
EBITDA$-229.68M$-2.41B$-2.33B
Basic EPS$-16.53$-31.75$-30.69
Diluted EPS$-16.53$-29.23$-30.69

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 28, 24 | 11:50 AM
Q2 23Aug 17, 23 | 12:26 PM
Q4 22Mar 31, 23 | 11:52 AM

Peer Comparison


TickerCompany
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc.
APLSApellis Pharmaceuticals, Inc.
BPMCBlueprint Medicines Corporation
BGNEBeiGene, Ltd.
ERASErasca, Inc.
NRIXNurix Therapeutics, Inc.
AKROAkero Therapeutics, Inc.
KYMRKymera Therapeutics, Inc.
FHTXFoghorn Therapeutics Inc.
ASNDAscendis Pharma A/S
GLUEMonte Rosa Therapeutics, Inc.
KRYSKrystal Biotech, Inc.
DSGNDesign Therapeutics, Inc.
IMVTImmunovant, Inc.
LYELLyell Immunopharma, Inc.
STTKShattuck Labs, Inc.